$0.43 EPS Expected for Phibro Animal Health Corp (PAHC) This Quarter

Analysts expect that Phibro Animal Health Corp (NASDAQ:PAHC) will report earnings of $0.43 per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Phibro Animal Health’s earnings, with the lowest EPS estimate coming in at $0.41 and the highest estimate coming in at $0.44. Phibro Animal Health reported earnings per share of $0.38 in the same quarter last year, which indicates a positive year over year growth rate of 13.2%. The company is expected to announce its next earnings report on Monday, November 5th.

According to Zacks, analysts expect that Phibro Animal Health will report full-year earnings of $1.80 per share for the current year, with EPS estimates ranging from $1.75 to $1.87. For the next fiscal year, analysts forecast that the firm will report earnings of $1.89 per share, with EPS estimates ranging from $1.88 to $1.90. Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Phibro Animal Health.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Monday, August 27th. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.04. The company had revenue of $211.80 million during the quarter, compared to the consensus estimate of $209.27 million. Phibro Animal Health had a net margin of 7.90% and a return on equity of 39.81%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.39 earnings per share.

PAHC has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Phibro Animal Health from a “sell” rating to a “buy” rating and set a $53.00 target price for the company in a report on Thursday, August 30th. BidaskClub upgraded shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a report on Wednesday, August 8th. Morgan Stanley raised their price objective on shares of Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a report on Wednesday, August 29th. Finally, Barclays raised their price objective on shares of Phibro Animal Health from $31.00 to $33.00 and gave the stock an “underweight” rating in a report on Thursday, July 5th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $43.20.

In other news, CEO Jack Bendheim sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 6th. The shares were sold at an average price of $50.66, for a total value of $506,600.00. Following the completion of the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at $405,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel M. Bendheim sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $44.30, for a total transaction of $110,750.00. Following the completion of the transaction, the vice president now owns 2,500 shares of the company’s stock, valued at $110,750. The disclosure for this sale can be found here. Insiders sold 343,960 shares of company stock valued at $16,571,627 in the last quarter. Corporate insiders own 51.88% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in PAHC. Royal Bank of Canada boosted its position in shares of Phibro Animal Health by 2,104.6% in the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after acquiring an additional 3,641 shares during the period. Meeder Asset Management Inc. boosted its position in shares of Phibro Animal Health by 149.2% in the second quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock valued at $206,000 after acquiring an additional 2,676 shares during the period. Piedmont Investment Advisors LLC bought a new position in shares of Phibro Animal Health in the second quarter valued at approximately $213,000. Highbridge Capital Management LLC bought a new position in shares of Phibro Animal Health in the first quarter valued at approximately $214,000. Finally, Janus Henderson Group PLC bought a new position in shares of Phibro Animal Health in the second quarter valued at approximately $222,000. Institutional investors own 49.19% of the company’s stock.

Shares of PAHC stock traded up $0.35 on Thursday, hitting $42.80. The stock had a trading volume of 3,251 shares, compared to its average volume of 189,440. The company has a market cap of $1.71 billion, a P/E ratio of 24.60, a P/E/G ratio of 2.44 and a beta of 0.90. The company has a debt-to-equity ratio of 1.62, a current ratio of 2.90 and a quick ratio of 1.66. Phibro Animal Health has a 12-month low of $32.05 and a 12-month high of $54.62.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 26th. Stockholders of record on Wednesday, September 5th will be paid a $0.10 dividend. The ex-dividend date is Tuesday, September 4th. This represents a $0.40 annualized dividend and a dividend yield of 0.93%. Phibro Animal Health’s payout ratio is 22.99%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

Read More: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply